Hisamitsu Pharmaceutical Co.
Manufacturing · Japan · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
2-4-1 Marunouchi, Chiyoda-ku, Tokyo, 100...Phone Number
+81 352931720Website
www.hisamitsu.co.jpRevenue
$892.7 MillionStock Symbol
4530Industry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Hisamitsu Pharmaceutical Co.
Hisamitsu Pharmaceutical Co., Inc. is a pharmaceutical company that develops and markets prescription and over-the-counter pharmaceutical products using transdermal delivery systems technology. The company was founded in 1847 and is located in Saga, Japan.Explore more
Hisamitsu Pharmaceutical Co. Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hisamitsu Pharmaceutical Co. your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Hisamitsu Pharmaceutical Co. is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Hisamitsu Pharmaceutical Co. has recently received funding, and reach out quickly before it becomes old news!
Click to see if Hisamitsu Pharmaceutical Co. had a recent Job posting/layoffs
Earning: See what the market has to say on Hisamitsu Pharmaceutical Co. recently announced quarterly report
Hisamitsu Pharmaceutical Co., which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Hisamitsu Pharmaceutical Co. launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Hisamitsu Pharmaceutical Co. has new funding data
Congratulate Masked Content for being promoted to Masked Content at Hisamitsu Pharmaceutical Co.
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Hisamitsu Pharmaceutical Co. is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hisamitsu Pharmaceutical Co. is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hisamitsu Pharmaceutical Co..
Hisamitsu Pharmaceutical Co. Tech Stack
A closer look at the technologies used by Hisamitsu Pharmaceutical Co.
Hisamitsu Pharmaceutical Co. News & Media
Cold Pain Therapy Market Worth $2.4 Billion by 2027 - Exclusive Report by MarketsandMarkets™
Northbrook, IL 60062 -- (SBWIRE) -- 06/21/2022 -- In June 2021, Hisamitsu Pharmaceutical CO., Inc. (Japan) launched Air Salonpas Z, an analgesic and anti-inflammatory spray for muscle pain, bruises, and sprains, among other conditions. Read the full press release at http://www.sbwire.com/press-releases/cold-pain-therapy-market-worth-24-billion-by-2027-exclusive-report-by-marketsandmarketstm-1359307.htmNoven to Present Pivotal Study Results for Investigational Dextroamphetamine Transdermal System for Pediatric ADHD Patients
MIAMI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., (“Noven”) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced it will present the results of a multicenter, phase 2, laboratory classroom study which evaluated the safety and efficacy of its investigational dextroamphetamine transdermal system (“ATS”) in over 100 pediatric patients (ages 6-17 years) with ADHD at the 2021 virtual American Psychiatric Association (APA) Annual Meeting May 1-3, 202Hisamitsu America intros Salonpas arthritis pain gel
Salonpas Arthritis Pain Relief Gel contains prescription-strength diclofenac, which was approved for over-the-counter use in 2020 by the Food and Drug Administration.Noven Submits New Drug Application for Investigational Dextroamphetamine Transdermal System for ADHD
MIAMI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., (“Noven”) a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today confirmed it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system (“ATS”). Noven’s ATS, in 4.5mg/9 hours, 9.0 mg/9 hours, 13.5mg/9 hours and 18.0mg/9 hours dosage strengths, is an investigational therapy developed for the treatment of Att
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hisamitsu Pharmaceutical Co.
Sign Up For FreeTo access detailed company insights
Hisamitsu Pharmaceutical Co., Inc. is a pharmaceutical company that develops and markets prescription and over-the-counter pharmaceutical products using transdermal delivery systems technology. The company was founded in 1847 and is located in Saga, Japan.... Read More
